- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
3 Horrendous Health-Care Stocks This Week презентация
Содержание
- 1. 3 Horrendous Health-Care Stocks This Week
- 2. Has the so-called biotech bubble burst? Two
- 3. The biotech’s shares plunged more than 46%
- 4. It announced on Tuesday the completion of
- 5. Shares of the cloud-based health-care technology company
- 6. Castlight’s IPO was last week, with the
- 7. The stock of the biopharmaceutical company fell
- 8. This week’s decline appears to be a
- 9. While Castlight’s business model is compelling, the
- 10. Find out which stock The Motley Fool’s
Has the so-called biotech bubble burst? Two of this week’s most horrendous health-care stocks bolster the theory, while the third stock could simply be experiencing the effects of market gravity. Source:
Слайд 2Has the so-called biotech bubble burst? Two of this week’s most
horrendous health-care stocks bolster the theory, while the third stock could simply be experiencing the effects of market gravity.
Source: Wikimedia Commons
Слайд 3The biotech’s shares plunged more than 46% for the week.
Exelixis
(Nasdaq: EXEL)
Source: Yahoo! Finance
Слайд 4It announced on Tuesday the completion of an interim analysis of
Cometriq and that the phase 3 prostate cancer trial would continue to final analysis.
Many observers expected the study would be stopped early, as Johnson & Johnson’s Zytiga and Medivation’s Xtandi were.
Exelexis expects top-line data from the phase 3 study later this year.
Many observers expected the study would be stopped early, as Johnson & Johnson’s Zytiga and Medivation’s Xtandi were.
Exelexis expects top-line data from the phase 3 study later this year.
Why Exelixis got clobbered
Слайд 5Shares of the cloud-based health-care technology company dropped 27% this week.
Castlight Health (NYSE: CSLT)
Source: Yahoo! Finance
Слайд 6Castlight’s IPO was last week, with the stock vaulting nearly 150%
on its first day of trading.
With only $13 million in revenue, Castlight’s market cap hit $3 billion.
The backlash is apparently now under way, with plenty of critics.
Yahoo! Finance called Castlight the “most overpriced IPO of the century.”
With only $13 million in revenue, Castlight’s market cap hit $3 billion.
The backlash is apparently now under way, with plenty of critics.
Yahoo! Finance called Castlight the “most overpriced IPO of the century.”
Why Castlight’s stock careened
Слайд 7The stock of the biopharmaceutical company fell 24% this week.
Galena
Biopharma (Nasdaq: GALE)
Source: Yahoo! Finance
Слайд 8This week’s decline appears to be a continuation from last week’s
announcement of an SEC investigation.
The investigation stems from alleged questionable stock-promotions efforts by The DreamTeam Group, particularly involving the posting of positive articles about Galena.
Several online financial sites, including The Motley Fool, pulled articles related to the controversy over the past few months.
The investigation stems from alleged questionable stock-promotions efforts by The DreamTeam Group, particularly involving the posting of positive articles about Galena.
Several online financial sites, including The Motley Fool, pulled articles related to the controversy over the past few months.
Why Galena shares dropped
Слайд 9While Castlight’s business model is compelling, the stock really is overpriced
right now.
Galena could certainly come back with good news from cancer immunotherapy Neuvax.
Exelixis gets the nod as the most likely to rebound.
Continuation of the Cometriq study was disappointing, but the market overreacted, in my view.
Galena could certainly come back with good news from cancer immunotherapy Neuvax.
Exelixis gets the nod as the most likely to rebound.
Continuation of the Cometriq study was disappointing, but the market overreacted, in my view.
Best shot at bouncing back?
?
Слайд 10Find out which stock The Motley Fool’s chief investment officer selected
as the top pick for 2014 in our free report!
